Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.36 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3330200 | 0.75 | SCN9A (0.66) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3335377 | 0.72 | SCN9A (0.40) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3330437 | 0.71 | SCN9A (0.38) | SCN9AALDH1A1LMNA | |
| SCHEMBL3335371 | 0.71 | SCN9A (0.33) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3330818 | 0.70 | SCN9A (0.47) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL12314903 | 0.70 | SCN9A (0.52) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3330324 | 0.67 | SCN9A (0.36) | SCN9AALDH1A1 | |
| SCHEMBL3333886 | 0.66 | SCN9A (0.66) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3325392 | 0.65 | SCN9A (0.70) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3329217 | 0.65 | SCN9A (0.64) | SCN9ASCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885SCN7A 72/4885SCN5A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.